{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:05:32Z","timestamp":1789329932574,"version":"build-2803163510"},"reference-count":30,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/20523211.2024.2417399","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:37:57Z","timestamp":1729661877000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacovigilance: the evolution of drug safety monitoring"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-4075","authenticated-orcid":false,"given":"Muhammad Akhtar Abbas","family":"Khan","sequence":"first","affiliation":[{"name":"Health Services Academy, Islamabad, Pakistan"},{"name":"Drug Regulatory Authority of Pakistan","place":["Islamabad, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehreem","family":"Sara","sequence":"additional","affiliation":[{"name":"Drug Regulatory Authority of Pakistan","place":["Islamabad, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1051-3240","authenticated-orcid":false,"given":"Zaheer-Ud-Din","family":"Babar","sequence":"additional","affiliation":[{"name":"Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118820186.ch13a"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0534-1"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.006"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20210918.501"},{"key":"e_1_3_3_6_1","unstructured":"EU. (2008). European Commission. MEMO\/08\/782: Strengthening pharmacovigilance to reduce adverse effects of medicines. https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/memo_08_782."},{"key":"e_1_3_3_7_1","unstructured":"European Commission. (2022). Pharmacovigilance. https:\/\/ec.europa.eu\/health\/medicinal-products\/pharmacovigilance_en."},{"key":"e_1_3_3_8_1","unstructured":"European Medicine Agency. (2017). New EudraVigilance system is live. https:\/\/www.ema.europa.eu\/en\/news\/new-eudravigilance-system-live."},{"key":"e_1_3_3_9_1","unstructured":"European Medicine Agency. (2018). EudraVigilance operational plan. https:\/\/www.ema.europa.eu\/en\/documents\/other\/eudravigilance-operational-plan-milestones-2018-2020_en.pdf."},{"key":"e_1_3_3_10_1","unstructured":"European Medicine Agency. (2022). History of EMA. https:\/\/www.ema.europa.eu\/en\/about-us\/history-ema."},{"key":"e_1_3_3_11_1","volume-title":"Medicinal products in the European Union: The legal framework for medicines for human use","author":"European Parliament: Directorate-General for Parliamentary Research Services","year":"2015","unstructured":"European Parliament: Directorate-General for Parliamentary Research Services & Scholz, N. (2015). Medicinal products in the European Union: The legal framework for medicines for human use. In-depth analysis, Publications Office. https:\/\/data.europa.eu\/doi\/10.2861\/345854"},{"key":"e_1_3_3_12_1","unstructured":"FDA. (2022). MedWatch forms for FDA safety reporting. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/medwatch-forms-fda-safety-reporting."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0657-1"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jphsr\/rmac046"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy11010010"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.891954"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.789103"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200205000-00030"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2215"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7166.2002.tb05487.x"},{"key":"e_1_3_3_22_1","unstructured":"MHRA. (2022). Yellow card. https:\/\/yellowcard.mhra.gov.uk\/."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316620-000000000-00000"},{"issue":"1","key":"e_1_3_3_24_1","first-page":"108","article-title":"Dr . Frances Kelsey\u202f: Turning the thalidomide tragedy into food and drug administration reform","volume":"2","author":"Rice E.","year":"2007","unstructured":"Rice, E. (2007). Dr . Frances Kelsey\u202f: Turning the thalidomide tragedy into food and drug administration reform. International Journal Of Advance In Pharmacy, 2(1), 108\u2013110.","journal-title":"International Journal Of Advance In Pharmacy"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0572-8"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619892679"},{"key":"e_1_3_3_27_1","unstructured":"Uppsala Monitoring Centre. (2018). Making medicines safer (Uppsala Reports). https:\/\/who-umc.org\/media\/164267\/umc_making_medicines_safer_web.pdf."},{"key":"e_1_3_3_28_1","unstructured":"Uppsala Monitoring Centre. (2022). What is vigibase. https:\/\/who-umc.org\/vigibase\/."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-199607000-00005"},{"key":"e_1_3_3_30_1","volume-title":"The importance of pharmacovigilance","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. (2002). The importance of pharmacovigilance."},{"key":"e_1_3_3_31_1","unstructured":"World Health Organization. (2024). The WHO programme for international drug monitoring. https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/health-professionals-info\/pidm."}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2024.2417399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:01:51Z","timestamp":1772722911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2024.2417399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/20523211.2024.2417399"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2024.2417399","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2417399"}}